Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis

Eileen M. Raynor, Allen Butler, Margaret Guill, John P. Bent

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: To determine the benefit of nasally inhaled dornase alfa in cystic fibrosis (CF) sinusitis. Design: Retrospective chart review comparing postsurgical course, radiographic studies, and pulmonary function test results in patients who were treated with nasally inhaled dornase alfa with those in patients who were not treated with dornase alfa. Patients: Twenty consecutive patients with CF who underwent functional endoscopic sinus surgery from 1993 to 1997 were included in the study. Treatment with nasally inhaled dornase alfa was initiated in 5 of the 20 patients after they underwent functional endoscopic sinus surgery. Setting: Tertiary care academic center. Results: The dornase alfa-treated patients had less mucosal edema and no polyps at serial endoscopy over 3 years compared with the non- dornase alfa-treated patients. The patients who received nasally inhaled dornase alfa also underwent fewer revision functional endoscopic sinus surgical procedures (1.6 vs 3.2), even though there was essentially no change in pulmonary function test results in these patients. Conclusions: Sinusitis continues to be a major cause of morbidity in patients with CF. Symptomatic patients frequently require multiple drug regimens, including long-term systemic antibiotic therapy, topical and systemic steroid therapy, and antibiotic nasal irrigations. This preliminary study indicates the potential impact of nasally inhaled dornase alfa in controlling postoperative symptoms in CF sinusitis.

Original languageEnglish (US)
Pages (from-to)581-583
Number of pages3
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume126
Issue number5
StatePublished - May 2000
Externally publishedYes

Fingerprint

Sinusitis
Cystic Fibrosis
Respiratory Function Tests
Endoscopy
dornase alfa
Nasal Lavage
Anti-Bacterial Agents
Polyps
Tertiary Care Centers
Edema
Therapeutics
Steroids
Morbidity

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis. / Raynor, Eileen M.; Butler, Allen; Guill, Margaret; Bent, John P.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 126, No. 5, 05.2000, p. 581-583.

Research output: Contribution to journalArticle

@article{64c83bc7bb614c34b381374c5d3c47c5,
title = "Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis",
abstract = "Objective: To determine the benefit of nasally inhaled dornase alfa in cystic fibrosis (CF) sinusitis. Design: Retrospective chart review comparing postsurgical course, radiographic studies, and pulmonary function test results in patients who were treated with nasally inhaled dornase alfa with those in patients who were not treated with dornase alfa. Patients: Twenty consecutive patients with CF who underwent functional endoscopic sinus surgery from 1993 to 1997 were included in the study. Treatment with nasally inhaled dornase alfa was initiated in 5 of the 20 patients after they underwent functional endoscopic sinus surgery. Setting: Tertiary care academic center. Results: The dornase alfa-treated patients had less mucosal edema and no polyps at serial endoscopy over 3 years compared with the non- dornase alfa-treated patients. The patients who received nasally inhaled dornase alfa also underwent fewer revision functional endoscopic sinus surgical procedures (1.6 vs 3.2), even though there was essentially no change in pulmonary function test results in these patients. Conclusions: Sinusitis continues to be a major cause of morbidity in patients with CF. Symptomatic patients frequently require multiple drug regimens, including long-term systemic antibiotic therapy, topical and systemic steroid therapy, and antibiotic nasal irrigations. This preliminary study indicates the potential impact of nasally inhaled dornase alfa in controlling postoperative symptoms in CF sinusitis.",
author = "Raynor, {Eileen M.} and Allen Butler and Margaret Guill and Bent, {John P.}",
year = "2000",
month = "5",
language = "English (US)",
volume = "126",
pages = "581--583",
journal = "Archives of Otolaryngology",
issn = "2168-6181",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis

AU - Raynor, Eileen M.

AU - Butler, Allen

AU - Guill, Margaret

AU - Bent, John P.

PY - 2000/5

Y1 - 2000/5

N2 - Objective: To determine the benefit of nasally inhaled dornase alfa in cystic fibrosis (CF) sinusitis. Design: Retrospective chart review comparing postsurgical course, radiographic studies, and pulmonary function test results in patients who were treated with nasally inhaled dornase alfa with those in patients who were not treated with dornase alfa. Patients: Twenty consecutive patients with CF who underwent functional endoscopic sinus surgery from 1993 to 1997 were included in the study. Treatment with nasally inhaled dornase alfa was initiated in 5 of the 20 patients after they underwent functional endoscopic sinus surgery. Setting: Tertiary care academic center. Results: The dornase alfa-treated patients had less mucosal edema and no polyps at serial endoscopy over 3 years compared with the non- dornase alfa-treated patients. The patients who received nasally inhaled dornase alfa also underwent fewer revision functional endoscopic sinus surgical procedures (1.6 vs 3.2), even though there was essentially no change in pulmonary function test results in these patients. Conclusions: Sinusitis continues to be a major cause of morbidity in patients with CF. Symptomatic patients frequently require multiple drug regimens, including long-term systemic antibiotic therapy, topical and systemic steroid therapy, and antibiotic nasal irrigations. This preliminary study indicates the potential impact of nasally inhaled dornase alfa in controlling postoperative symptoms in CF sinusitis.

AB - Objective: To determine the benefit of nasally inhaled dornase alfa in cystic fibrosis (CF) sinusitis. Design: Retrospective chart review comparing postsurgical course, radiographic studies, and pulmonary function test results in patients who were treated with nasally inhaled dornase alfa with those in patients who were not treated with dornase alfa. Patients: Twenty consecutive patients with CF who underwent functional endoscopic sinus surgery from 1993 to 1997 were included in the study. Treatment with nasally inhaled dornase alfa was initiated in 5 of the 20 patients after they underwent functional endoscopic sinus surgery. Setting: Tertiary care academic center. Results: The dornase alfa-treated patients had less mucosal edema and no polyps at serial endoscopy over 3 years compared with the non- dornase alfa-treated patients. The patients who received nasally inhaled dornase alfa also underwent fewer revision functional endoscopic sinus surgical procedures (1.6 vs 3.2), even though there was essentially no change in pulmonary function test results in these patients. Conclusions: Sinusitis continues to be a major cause of morbidity in patients with CF. Symptomatic patients frequently require multiple drug regimens, including long-term systemic antibiotic therapy, topical and systemic steroid therapy, and antibiotic nasal irrigations. This preliminary study indicates the potential impact of nasally inhaled dornase alfa in controlling postoperative symptoms in CF sinusitis.

UR - http://www.scopus.com/inward/record.url?scp=0034122713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034122713&partnerID=8YFLogxK

M3 - Article

VL - 126

SP - 581

EP - 583

JO - Archives of Otolaryngology

JF - Archives of Otolaryngology

SN - 2168-6181

IS - 5

ER -